|
|
name  click to compare prices |
| Alli, Altabax, Augmentin, Avandamet | | Bactroban, Breathe Right | | CNS, Cutivate | | FiberChoice | | Glaxo Smithkline | | Hedex | | Iodosan | | Lactacyd, Levitra | | Macleens | | Panadol, Paxil, Prepandrix | | Reliant Laboratories | | Sirtris, Sirtris, Solpadeine | | Valda |
» Shop local, ethical and at the best price on Ethishop  |
|
| |
|
| shareholder | country | % | source |
|
year | business source |
| 2006 | GlaxoSmithKline sells 23% of the vaccines bought in the world. | Les Echos |
| 2006 | GlaxoSmithKline is Europe's biggest drugmaker. | Reuters |
| 2006 | GlaxoSmithKline is the world's second-largest pharmaceutical group. | Les Echos |
| 2004 | GlaxoSmithKline sells 25% of the tobacco substitutes bought in France. | Les Echos |
|
| country | address & contact : production type incentive source |
 China | Shanghai, Glaxo plans to have 1,000 scientists working at the facility in 10 years. : Production, research facility |
| China | PharmaValley, Shanghai : Les Echos |
 Suriname | "Bioventure" with Conservation International : bioprospection Alternet |
|
| year name | photo position; compensation source |
|
| year | employees <> | social impact : country source |
| 2009 | -1341 | Internal restructuring: Glaxo cuts 798 jobs in Evreux (Eure), 30 jobs in Ulis (Essonne), 13 jobs in Notre-Dame de Bondeville (Seine-Maritime), 500 medical representatives jobs and 146 at its headquarters of Marly-le-Roi, in the Yvelines.: France | Les Echos |
| 2008 | -620 | Closure/Bankruptcy: GlaxoSmithKline closes its Dartford plant because ot the competition of the generic drug makers.: United Kingdom | Les Echos |
| 2008 | 17000 -350 | Internal restructuring: GlaxoSmithKline Plc is axing around 350 jobs in research and development as part of an ongoing restructuring program. "We continue to reshape our R&D operations to take advantage of new scientific opportunities and improve GSK's productivity. Regrettably some job reductions are necessary and we will do everything we can to support those employees who are affected," a spokesman said.: | Reuters |
| 2004 | 100019 -100 | | European Restructuring Monitor |
| 2001 | -1800 | | Financial Times |
|
| year | employees <> | social impact : country source |
|
| year | country : consequences source |
| 2009 | France : GlaxoSmithKline was judged " entirely responsible for the detrimental consequences resulting from the defect of its vaccine Engerix B" , and condemned by the court of Nanterre to give 400.000 euros to an young woman affected by multiple sclerosis after having vaccinated against hepathitis B. | Les Echos |
| 2004 | United States of America brand: Paxil : Glaxo avait versé 2,5 millions de dollars pour mettre fin aux poursuites de la FDA pour avoir caché les risques que présente l'anti-dépresseur Paxil administré à des enfants et adolescents. | Le Revenu |
|
| year | country : consequences source |
|
| year | financial misdemeanor | sales | income | | buyback | source |
| 2006 |
| 45,5 | 8,75 | | | billion US$ | |
| 2006 |
GlaxoSmithKline is fined 10 millions euros for "predatory pricing" by the French Commission on competition. GlaxoSmithKline sold the generic version of the Zinnat antibiotic at prices lower than its own purchase prices, in order to evict other manufacturers such as Flavelab which was selling similar generics. After Flavelab was driven out of the market, GlaxoSmithKline appreciably raised its prices over the two years which followed, recovering very largely the losses authorized for the period of predation. |
| | | | | | Les Echos |
| 2005 |
| 37,27 | 5,74 | | | billion US$ | |
| 2005 |
GSK a payé 150 millions de dollars pour solder à l'amiable un différend portant sur des accusations du gouvernement américain, selon lesquelles il aurait pratiqué des prix élevés et frauduleux sur deux de ses médicaments. |
| | | | | | Les Echos |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | | | | Bloomberg |
| 2005 |
A federal judge has granted final approval to SmithKline Beecham's $65 million settlement of a class action antitrust suit brought by consumers who said they paid inflated prices for Paxil, a popular anti-depressant drug. The suit alleged that SmithKline illegally maintained a monopoly by filing a series of "sham" patent lawsuits that were designed to delay any generic version of the drug from reaching the market. Glaxo settles the suit for 14 million dollars. |
| | | | | | Reuters |
| 2004 |
Charged by the US IRS with underpaying taxes of $US 5.2 billion on US profits earned between 1989 and 1996. |
| 39,22 | 5,26 | | | billion US$ | |
| 2004 |
Agreed to pay $92 million to settle antitrust cases involving the antibiotic product Augmentin. |
| | | | | | Bizjournals.com |
| 2004 |
Glaxo is facing fraud claims for suppressing at least four different studies showing that Paxil was no more effective than a placebo and at worst was harmful, while promoting heavily the drug boasting of its efficacy and safety. |
| | | | | | The Guardian |
| 2004 |
Une centaine d'employés de GSK poursuivis pour corruption et associations de malfaiteurs et soupçonnées d'être impliquées dans un système de corruption mis en place par la branche italienne du géant pharmaceutique britannique. |
| | | | | | France 2 |
| 2003 |
| 21,44 | 4,48 | | 0,836 | billion UK£ | |
| 2003 |
Surfacturation: a changé le nom de ses médicaments pour les écouler plus cher à l'administration fédérale états-unienne: amende de 89 millions de $US. |
| | | | | | L'Expansion |
| 2002 |
| 21,21 | 3,92 | | | billion Eu€ | |
| 2002 |
| | | | 2,2 | billion UK£ | The Motley Fool |
| 2002 |
Evidence of a nationwide "bribery system" in which doctors allegedly prescribed 7-8% more Glaxo products each year in return for "freebies" such as Caribbean trips, stereo systems and wine. |
| | | | | | The Guardian |
| 2002 |
1600 doctors across Germany are under investigation for allegedly taking bribes such as free holidays in exchange for prescribing Glaxo drugs |
| | | | | | Financial Times |
| 2001 |
| | | | 1,3 | billion UK£ | The Motley Fool |
| 2001 |
| 29,84 | 4,5 | | | billion US$ | |
| 2000 |
| 18,08 | 0,07 | | | billion Eu€ | |
| 1995 |
Allegedly bribed Italian health ministry officials |
| | | | | | The Guardian |
|
| year | financial misdemeanor | sales | income | assets | buyback | source |
|
| year | purpose : intermediary/lobby : institution source |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate  translate | Washington Post |
| 2000 | Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translate | EFPIA |
|
| year | purpose : intermediary/lobby : institution source |
|
| year | donator | country | amount | source |
| 2006 | Etat | France | 15 million Eu€ | Les Echos |
|
| year | donator | country | amount | source |
|
| year | dubious practice : image source |
| 2007 | Disinformation: GlaxoSmithKline attempted to stifle and intimidate physicians who initially expressed concerns that the diabetes drug Avandia was linked to higher risk of heart attacks, the Wall Street Journal reported. As early as 2000 a Maryland doctor linked the drug to congestive heart failure. The company responded by asking the hospital's chief physician to keep that physician from talking about it with other doctors at the hospital.: | Integrity in Science |
| 2007 | Disinformation: In early September, "major newspapers reported the alarming news that suicides among young people were on the rise because of a precipitous drop in the use of antidepressants," writes Alison Bass. The academic study the news articles were based on concluded that new safety warnings for young people using antidepressant drugs had discouraged doctors from writing prescriptions for depressed youths. But there's a hole in that argument: "while there was indeed an upturn in suicide rates among youths ... the number of prescriptions for antidepressants in the same age group remained basically unchanged." Bass points out that the pharmaceutical companies that make antidepressants might "benefit from the latest alarm about an apparent upturn in youth suicide rates. ... These companies have an enormous stake in reversing the current FDA warnings." Pfizer, which makes the antidepressant Zoloft, did provide $30,000 for the academic study, and the study's lead authors have ties to Pfizer, GlaxoSmithKline and Wyeth Pharmaceuticals. "This isn't the first time that suicide rates have been trotted out as a public relations weapon," Bass adds. "Proponents of psychotropic drugs have long argued that suicide rates ... fell after" such drugs were introduced, though the decline began well before the drugs were widely prescribed.: | Boston Globe |
| 2005 | Disinformation: In Fall 2005, the company will begin "an extensive state-by-state media blitz," paralleling its "grassroots outreach." PR Week reported, "Glaxo will target local media markets in each state - outlets that do not often have the chance to communicate directly with pharmaceutical executives." GSK's Pucci said that local reporters were easier for the drug company to deal with. "These folks are hungry for news," he said. "They'll print everything we say … without the political spin." GSK hired two PR firms for the media work, but declined to name them.: | Sourcewatch |
| 2005 | slogan: Do more, feel better, live longer.; | |
| 2005 | Soutient l'exposition « Valda toujours » au musée des Arts Décoratifs - Musée de la Publicité de Paris où seront rassemblées des publicités originales sous forme d’affiches, de plaques émaillées et d’automates.: value: Culture; | |
| 2005 | Disinformation: Voyage gratuit pour une trentaine de journalistes français pour se familiariser avec le traitement de l'asthme au Québec: public relations: V | Cyberpresse |
| 2004 | Disinformation: In March 2004, the Canadian Medical Association Journal published excerpts from a GSK "internal document" that advised staff "to withhold clinical trial findings in 1998 that indicated the antidepressant paroxetine (Paxil in North America and Seroxat in the UK) had no beneficial effect in treating adolescents." The GSK memo recommended, in part, that the company needed to "effectively manage the dissemination of these data in order to minimize any potential negative commercial impact" and stated that "It would be commercially unacceptable to include a statement that efficacy had not been demonstrated, as this would undermine the profile of paroxetine.": | Sourcewatch |
| 2004 | Disinformation: In spring 2004, GSK launched a "grassroots outreach" effort, sending "sales representatives to deliver its message in front of the religious, fraternal, and other community groups to which they belong." A year into the effort, PR Week reported that GSK's standing had improved by 13 points, according to a Harris Interactive poll. "Clearly the grassroots campaign is having an impact," said Michael Pucci, Glaxo's VP of external advocacy.: | Sourcewatch |
| 2002 | Disinformation: Euro RSCG Vitesse: public relations: E | CB-News |
| 2001 | ad budget: 1130 million US$; | Advertising Age |
| 2000 | ad budget: 1066 million US$; | Advertising Age |
|
|
|
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
